Under the Radar: Lucence’s take on the global cancer diagnostics market surpassing US$258.54b by 2030, Its LiquidHALLMARK cancer detection blood test, treading the fine line between pricing products affordably and achieving business objectives

Your Way Home with Hongbin Jeong · Feb 24, 2023 · 13m

Are you afraid of having your blood drawn? But what if the blood test could detect cancer causing genetic mutations and viruses, and allow for early treatment? I’m asking this because we are going to look at a company called Lucence, which makes blood tests to detect cancers. Founded in 2016, Lucence was spun off from the Agency for Science, Technology and Research (A*STAR). It had in 2019 unveiled a blood test called LiquidHALLMARK that detects 14 types of cancers, 50 genetic mutations and two viruses. Lucence had said then that LiquidHALLMARK is the world's first blood test that…